Parkinson Disease Psychosis Clinical Trial
Official title:
Unravelling Dysfunctional Brain Networks in Patients With Parkinson's Disease Suffering From Presence Hallucination
Investigation on how robotically mediated sensorimotor stimulation induces and triggers presence hallucinations in patients with Parkinson disease
Parkinson's Disease (PD) is primarily known and characterized by motor symptoms such as
tremor, rigidity and bradykinesia. However, a significant number of non-motor symptoms also
accompany the unfolding of this disease. In fact, hallucinations are experienced by
approximately 60% of the patients. The most common and amongst one of the earliest
hallucinations in Parkinson's Disease, is the Presence Hallucination (PH), i.e., the strange
sensation of perceiving someone behind when no one is actually there. In the present study
the researchers aim at investigating the behavioural and neural mechanisms underlying
symptomatic PH in PD. To do so the researchers intend to induce the PH in a repeated and
controlled manner in the MRI scanner, with an extensively verified paradigm which gives rise
to this sensation by means of robotically-mediated sensorimotor stimulation. This setup has
in fact been shown to trigger the occurrence of symptomatic PH in these patients. The
possibility to induce PH while the patient is in the MRI will allow the researchers to
investigate online the brain networks associated with it.
With analysis on the fine brain connectivity changes during PH-induction, the investigators
intend to pinpoint the exact mechanism behind the appearance of this hallucination in these
patients, in a similar fashion to previous work with the PH-induction in healthy individuals.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05824728 -
Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
|
Phase 2 | |
Terminated |
NCT03152292 -
The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study
|
||
Withdrawn |
NCT05344365 -
A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
|
Phase 2 | |
Recruiting |
NCT05357612 -
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
|
Phase 4 | |
Completed |
NCT06450184 -
Bioequivalence Study of Pimavanserin 34 mg Capsule
|
Phase 1 | |
Completed |
NCT04292223 -
Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
|
Phase 4 | |
Completed |
NCT02969369 -
A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis
|
Phase 2 | |
Not yet recruiting |
NCT05995782 -
A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
|
Phase 1 | |
Recruiting |
NCT04592965 -
Hallucinations in Parkinson's Disease
|
N/A | |
Completed |
NCT05240339 -
Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)
|
||
Recruiting |
NCT03661125 -
SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis
|
Early Phase 1 |